ACS

STOPDAPT-2 ACS: Clopidogrel Monotherapy after ACS

Visual Abstract Summary for the STOPDAPT-2 ACS Trial Question Is 1–2 months of dual antiplatelet therapy (DAPT) followed by clopidogrel monotherapy noninferior to 12 months of DAPT with aspirin and clopidogrel in patients with acute coronary syndromes (ACS)? Design Key … Read More

ULTIMATE-DAPT: Ticagrelor Monotherapy after ACS

“ULTIMATE-DAPT” trial summary. It presents the results of a clinical trial comparing the use of ticagrelor alone versus the combination of ticagrelor and aspirin following percutaneous coronary intervention (PCI) in patients with Acute Coronary Syndrome (ACS) from month 1 to … Read More

CURRENT-OASIS 7: Double Dose Clopidogrel or ASA in ACS

Year: 2010 Title: CURRENT-OASIS 7 Subtitle: Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing PCI for ACS Type of Trial: Double-blind, Randomized Factorial Trial Objective: To evaluate whether a higher dosage of clopidogrel with aspirin (two … Read More

FIRE Trial: Complete PCI in MI in Older Patients

The FIRE trial, published in the New England Journal of Medicine in 2023, was a multicenter, randomized controlled trial that aimed to evaluate the benefits of complete revascularization versus culprit-lesion-only percutaneous coronary intervention (PCI) in older patients (≥75 years of … Read More

T-PASS Trial: A Shift in Post-Stenting Treatment for ACS

T-PASS Trial Summary The management of Acute Coronary Syndrome (ACS) after stenting has been a hot topic for medical researchers for years. The recent T-PASS Trial in 2023 has shed light on the possible advantages of shifting from the conventional … Read More

RITA 3 Trial: Interventional vs. Conservative Strategy in UA/NSTEMI

RITA 3 Trial Summary Background: Methods: Findings: Interpretation: Key Takeaways: Source

SECURE PCI Trial Summary: Loading Atorvastatin in ACS

2018 SECURE-PCI TRIAL Effect of loading dose of atorvastatin prior to planned percutaneous coronary intervention on major adverse cardiovascular events in acute coronary syndrome double-blind, multicenter, randomized controlled trial Objective: To determine if periprocedural loading doses of atorvastatin decrease 30-day … Read More

POPular AGE Trial Summary: Antiplatelet agent in NSTEMI

2020 POPULAR AGE TRIAL Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome multicenter, randomized controlled trial Objective: To evaluate the effectiveness of clopidogrel compared with ticagrelor or prasugrel among patients ≥70 … Read More